Video number 31 of the channel, today talking about the Novavax SARS-CoV-2 vaccine NVX-CoV2373 to prevent COVID19. This is a subunit vaccine with an adjuvant and I go into what that entails. Data from the phase I trial has just been released following good preclinical data from bonobos and mice. The early part of the study looking at 131 people shows promising signs. All developed good antibody responses compared to control, all had good neutralising antibody response (work we were involved with, but no financial interest) and only minimal adverse events. The antibody response generated seems comparable or better to that of people who developed COVID19. All in all, the vaccine appears to be tolerable and immunogenic, promising signs at this early stage.
Papers discussed:
Preclinical data from bonobos and mice on BioRxiv –
Phase I patient data on MedRxiv –
Press release –
Previous videos regarding other vaccines in reverse chronological order:
Promising news for ChAdOx/Oxford SARS2 coronavirus vaccine –
More on ChAdOx vaccine to SARS2 coronavirus to protect against COVID19 –
ChAdOx (Oxford) vaccine to SARS2 coronavirus/COVID19 – this looks promising –
Timestamps
0:00:36 – Disclosure about the fact I have been involved with this research but have no financial interest
0:01:13 – Discussion of some other vaccine platforms I’ve discussed before (ChAdOx and Moderna). Also a discussion of how immunity develops and how a vaccine is designed to work
0:03:38 – Going into discussing a different approach of subunit vaccines (as done by Novavax)
0:04:43 – The Novavax vaccine approach summarised
0:06:05 – Into the studies looking at the NVX-CoV2373 vaccine candidate in lab animals and then in humans in the phase I study
0:12:12 – Concluding remarks
Please keep subscribing for updates of new videos, or follow me on Twitter – @StuartMWeston
And importantly through all this, stay safe, wash you hands, wear a mask, keep calm and carry on.
